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Abstract
Background: The family of 14-3-3 proteins plays an important role in cancer biology by interfering
with intracellular signalling pathways and cell cycle checkpoints. The 14-3-3σ isoform acts as a
tumor suppressor and is often inactivated during tumor development.
Results: Here, we demonstrate enhanced CpG methylation of the 14-3-3σ gene in lymph node
and cutaneous melanoma metastases compared with primary tumors, associated with dramatically
reduced mRNA expression. In line with this, treatment of different metastatic melanoma cell lines
with 5-aza-2'-deoxycytidine (5-Aza-CdR), a potent inhibitor of cytosine methylation, significantly
induces 14-3-3σ protein expression. Additional treatment with histone deacetylase inhibitor 4-
phenylbutyric acid (Pba) further enhances 14-3-3σ expression. Induction of 14-3-3σ expression by
5-Aza-CdR/Pba treatment leads to almost complete inhibition of cell proliferation, with cells
predominantly arrested in G2-M. The antiproliferative effect of 5-Aza-CdR/Pba was reversed in 14-
3-3σ knockdown cells. Similarly, melanoma cell lines stably overexpressing 14-3-3σ show
dramatically reduced cell proliferation rates. Moreover, synchronous 14-3-3σ stably
overexpressing cells do not progress through cell cycle, but display a permanent increase in the
population of 4n  DNA containing cells. Interestingly, overexpression of 14-3-3σ induces
senescence of melanoma cells and is involved in melanoma cell senescence under genotoxic stress.
Finally, 14-3-3σ knockdown supports migratory capacity of melanoma cells in vitro, while 14-3-3σ
overexpression has opposing effects.
Conclusion: Taken together, the present report indicates that epigenetic silencing of 14-3-3σ
might contribute to tumor progression in malignant melanoma via loss of cell cycle control,
impaired cellular senescence program and support of migratory capacity.
Background
Malignant melanoma is a highly aggressive tumor with
poor prognosis in the metastatic stage [1,2]. The molecu-
lar events underlying initial tumor development and fur-
ther tumor progression are still poorly understood [2-4].
In a recent series of large-scale genetic studies, activating
mutations were found in BRAF and NRAS oncogenes in a
significant proportion of primary melanomas [5-8]. How-
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ever, since also benign melanocytic nevi as classical
melanoma precursor lesions showed a high percentage of
activating  BRAF  mutations, further molecular mecha-
nisms might contribute to primary tumor development
[9,10]. In a more recent genome-wide RNA-interference
screening targeting 28,000 genes, 17 genes were identified
required to block uncontrolled proliferation of melano-
cytes in the presence of activated BRAF  (BRAFV600E).
Among these genes with tumor suppressor function, insu-
lin-like growth factor binding protein 7 (IGFBP7) appears
to play an outstanding role. Interestingly, the IGFBP7 gene
is often silenced by epigenetic mechanisms in primary
melanomas, and might thereby contribute to early malig-
nant transformation of malignant melanoma. However,
the functional relevance of these findings in human
melanoma remains to be shown. Based on current find-
ings, it appears that several mechanisms act together dur-
ing malignant transformation and further progression of
melanoma cells. Among these are activating or inactivat-
ing mutations of members of the Akt signalling pathway,
namely phosphatidylinositol 3-kinase CA (PI3KCA), Akt
kinase and the tumor suppressor phosphatase and tensin
homolog (PTEN) [2,5].
Earlier reports showed that classical tumor suppressor
molecules such as p16 and retinoblastoma protein might
play role in malignant melanoma development [4]. It is
well established that familial melanoma patients display
mutations in the tumor suppressor protein p16
(CDKN2A) in almost half of the cases. In line with this,
mice genetically engineered for p16 inactivation and over-
expression of activated Ras develop primary melanomas
and distant metastases [4]. However, only a small percent-
age of non-familial melanoma patients show inactivating
mutations in the CDKN2A tumor suppressor gene. Fur-
ther tumor suppressor molecules might thus be involved
in melanoma suppression, the loss of which might give
rise to primary tumors as well as metastases.
The family of 14-3-3 proteins comprises seven small mol-
ecules termed 14-3-3β,  γ,  ε,  η,  σ,  τ, and ζ, which are
expressed in a large variety of different tissues [11,12]. Ear-
lier reports suggested that expression of 14-3-3σ was
restricted to cells of epithelial origin, in particular strati-
fied epithelia which led to the designation stratifin (SFN).
14-3-3 proteins act as phosphoserine- and phosphothreo-
nine-binding proteins binding to the consensus motif
RSXpS/TXP [13]. The list of interacting proteins comprises
a large variety of different molecules, many of which are
involved in intracellular signalling, apoptosis and cell
cycle regulation, such as protein kinase C (PKC), RAF1,
small G proteins, BAD, and CDC25C [11]. During inter-
action with RAF1, a member of the oncogene RAS/RAF/
MEK/Erk pathway, dimeric 14-3-3 proteins exert a dual
function. They maintain Raf1 in an inactive state in the
absence of activated RAS, but stabilize the active confor-
mation of Raf1 after pathway activation [14]. However,
the exact mechanism of how RAF-1 is regulated by 14-3-3
proteins is still unknown. In general, 14-3-3 proteins are
involved in cell cycle machinery at different checkpoints
in order to allow DNA damage repair or to establish a per-
manent arrest of cells that have severe damage [12,15].
In more recent investigations using tandem affinity purifi-
cation combined with multidimensional protein identifi-
cation, 117 proteins were identified as putative
interaction partners of 14-3-3σ [16]. Among these were 92
with known biological functions, many of which impli-
cated in mitogenic signalling such as APC, A-RAF, B-RAF,
and c-RAF, casein kinase II, PI3K-C2β, or cell cycle regula-
tion such as AJUBA, WEE1, and c-TAK1. Together, these
findings further emphasized the role of 14-3-3σ as a
major regulator of cell cycle control [12,15].
There is an increasing body of evidence that inactivation
of 14-3-3σ is involved in tumor development in a variety
of malignant tumors [11]. First, 14-3-3σ is a well-known
downstream target of tumor suppressor p53, which is
inactivated in almost half of all cancers [17]. Second, it is
involved in stabilization and activation of p53 in a posi-
tive feedback loop and overexpression of 14-3-3σ leads to
reduced tumorigenicity of oncogene expressing NIH 3T3
cells [18,19]. Third, absence of 14-3-3σ is associated with
increased genomic instability leading to the so-called
mitotic catastrophe [20]. Finally, it has been shown that
14-3-3σ has a CpG-rich region (CpG island) within its
first exon, which is hypermethylated in breast cancer [21],
hepatocellular carcinoma [22], ovarial [23] and prostate
cancer [24], with consecutive gene silencing. Together, 14-
3-3σ appears to play an important role in primary tumor
development. However, little is known about its possible
contribution to tumor metastasis.
In the present report, the 14-3-3σ gene showed enhanced
methylation in lymph node and cutaneous melanoma
metastases compared with primary tumors, and gene
methylation was associated with significant 14-3-3σ
downregulation. Treatment of melanoma cells with meth-
ylation inhibitor 5-Aza-CdR and histone deacetylase
inhibitor Pba led to a dramatic increase of 14-3-3σ expres-
sion associated with almost complete inhibition of cell
proliferation. Similarly, 14-3-3σ overexpression resulted
in cell cycle arrest and induction of melanoma cell senes-
cence. These findings implicate an important role of 14-3-
3σ in melanoma metastasis.Molecular Cancer 2009, 8:53 http://www.molecular-cancer.com/content/8/1/53
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Results
14-3-3σ mRNA expression is downregulated in melanoma 
metastases compared with primary melanomas
Previously, we were able to show in a large-scale gene
expression study that 14-3-3σ was the most significantly
downregulated gene in cutaneous melanoma metastases
compared with primary melanomas [25]. In order to fur-
ther substantiate and extend these findings, quantitative
real-time PCR was performed for 14-3-3σ gene expression
in an independent set of laser-microdissected primary
melanomas, lymph node and cutaneous metastases. As
shown in Figure 1, mean 14-3-3σ gene expression levels
were close to 10-fold higher in primary tumors compared
with metastases. Expression levels in both types of metas-
tases, lymph node (ln) and cutaneous (s) metastases, were
very similar. Taken together, melanoma progression
appears to be associated with a significant downregula-
tion of 14-3-3σ expression.
The 14-3-3σ gene shows enhanced methylation in 
melanoma metastases compared with primary melanomas
Epigenetic silencing of tumor suppressor genes is a com-
mon finding in primary malignancies [26]. As mentioned
above, 14-3-3σ has been shown to be silenced in a series
of primary tumors via gene methylation. However, little is
known about silencing of 14-3-3σ gene during tumor
metastasis. Here, 14-3-3σ gene methylation was analyzed
in two different tumor tissues representing locoregional
(lymph node) and distant (cutaneous) metastases, using
methylation-specific PCR (MSP). Primers were spanning
the region between CpG dinucleotides 3 and 9 of the first
exon of the 14-3-3σ gene, commonly methylated in a vari-
ety of tumors. Representative PCR products generated by
MSP and separated by agarose gels are shown in Figure 2a.
All tumors tested were methylated at these CpG dinucle-
otides, but to a different extent. The percentage of methyl-
ated alleles in primary tumors was significantly lower
than that of both metastasis groups. Figure 2b summa-
rizes data obtained from 15 primary melanomas, 20
lymph node (ln) metastases and 19 cutaneous (s) metas-
tases, respectively. Taken together, the level of CpG meth-
ylation of the 14-3-3σ gene in malignant melanoma
increases during tumor progression. 14-3-3σ gene methyl-
ation might contribute to 14-3-3σ gene downregulation
during melanoma metastasis.
Treatment of melanoma cells with 5-Aza-CdR and Pba 
induces 14-3-3σ expression in melanoma cell lines
To further substantiate the notion that downregulation of
the 14-3-3σ gene in melanoma cells might be due to epi-
genetic silencing by gene hypermethylation, metastatic
cell lines SK-Mel-19, SK-Mel-29, and SK-Mel-147, all
showing more than 50% methylated 14-3-3σ alleles (data
not shown), were treated with DNA methyltransferase
inhibitor 5-Aza-CdR, deacetylase inhibitor Pba, and a
combination of both, respectively. As shown in Figure 3a,
treatment with both substances significantly induced 14-
3-3σ protein expression, with 5-Aza-CdR having a signifi-
cantly greater effect than Pba. Similar results were
obtained in all three cell lines, indicating that epigenetic
silencing of 14-3-3σ via gene methylation is a general phe-
nomenon in melanoma cells. Combined treatment with
both substances further increased 14-3-3σ expression
rates. In summary, these findings showed that 14-3-3σ
expression can dramatically be induced by demethylating
agents such as 5-Aza-CdR. Combined treatment of 5-Aza-
CdR with Pba further increased 14-3-3σ expression, which
might be due to the fact that methylation and deacetyla-
tion act cooperatively during gene silencing.
Induction of 14-3-3σ by 5-Aza-CdR and Pba induces cell 
cycle arrest in G0-G1 and G2-M phase of cell cycle
14-3-3σ is a major cell cycle checkpoint molecule inhibit-
ing uncontrolled mitosis and proliferation of cells after
DNA damaging stresses, with consecutive G2-M and (to a
lesser extent) G0-G1 arrest. To address the question
whether induction of 14-3-3σ expression after demethyl-
ation/inhibition of histone deacetylation impacts on cell
cycle regulation in melanoma cells, cell cycle analyses
14-3-3σ mRNA is downregulated in melanoma metastases  compared with primary melanomas Figure 1
14-3-3σ mRNA is downregulated in melanoma 
metastases compared with primary melanomas. 
Total mRNA was extracted from melanoma cells excised by 
laser-capture microdissection from primary melanomas (n = 
11), lymph node (n = 10) and cutaneous metastases (n = 12), 
respectively. Quantitative real-time PCR was performed and 
relative mRNA expression levels are given as means +/- 
S.E.M. MM, primary melanomas; Meta (ln), lymph node 
metastases; Meta (s), cutaneous metastases.Molecular Cancer 2009, 8:53 http://www.molecular-cancer.com/content/8/1/53
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The 14-3-3σ gene shows enhanced methylation in melanoma  metastases compared with primary melanomas Figure 2
The 14-3-3σ gene shows enhanced methylation in 
melanoma metastases compared with primary 
melanomas. Methylation of the 14-3-3σ gene was analyzed 
by methylation-specific PCR. For this purpose genomic DNA 
extracted from laser-microdissected melanoma tissues was 
bisulfite-treated and subjected to PCR amplification of the 
14-3-3σ gene with primers specific for either unmethylated 
(U) or methylated (M) DNA alleles. (a) The percentage of 
methylated fraction is given for a representative set of 
tumors in each group after densitometric quantification of 
the PCR products separated by agarose gel electrophoresis. 
(b) Summary of the percentages of methylated alleles of all 
samples tested (15 primary melanomas, 20 lymph node 
metastases and 19 cutaneous metastases). Data are given as 
means +/- SD, P values represent statistical significance after 
applying Student's t-test. MM, primary melanomas; Meta (ln), 
lymph node metastases; Meta (s), cutaneous metastases.
Treatment of melanoma cells with 5-Aza-CdR, Pba, and 5- Aza-CdR/Pba, respectively, induces 14-3-3σ expression and  leads to inhibition of cell cycle progression Figure 3
Treatment of melanoma cells with 5-Aza-CdR, Pba, 
and 5-Aza-CdR/Pba, respectively, induces 14-3-3σ 
expression and leads to inhibition of cell cycle pro-
gression. (a) 14-3-3σ immunoblot analyses of melanoma cell 
lines SK-Mel-19, SK-Mel-29 and SK-Mel-147, treated with 5-
Aza-CdR (3 μM), Pba (3 mM), and a combination of both, 
respectively, for indicated times points or left untreated. (b) 
Cell cycle analysis of melanoma cell line SK-Mel-147 by flow 
cytometry after treatment as described in (a). Data are given 
as mean values +/- SD of four independent experiments.Molecular Cancer 2009, 8:53 http://www.molecular-cancer.com/content/8/1/53
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were performed. SK-Mel-147 melanoma cells were treated
with 5-Aza-CdR, Pba, and a combination of both, respec-
tively, stained with BrdU and analyzed by flow cytometry.
As shown in Figure 3b and Additional File 1, 5-Aza-CdR
induced 14-3-3σ expression and dramatically reduced the
number of cells in S-phase, paralleled by a slightly
increased number of cells in G0-G1 and a significantly
increased number of cells in G2-M. Pba alone had less
dramatic effects. A combination of both further reduced
the number of cells in S-phase and increased the number
of cells in G2-M, compared with 5-Aza-CdR alone.
To further analyze the specific contribution of 14-3-3σ to
5-Aza-CdR/Pba-induced cell cycle arrest, melanoma cells
were stably transduced with 14-3-3σ shRNA and 14-3-3σ
cDNA. In preliminary experiments, a series of 7 different
shRNAs have been tested (data not shown) and the one
with the most significant gene knockdown (si14-3-3-B4)
was used in cell cycle experiments together with a shRNA
with no downmodulating effect on 14-3-3σ (si14-3-3-
B7). As demonstrated in Figure 4a (upper panel), the
inhibitory effects of 5-Aza-CdR/Pba treatment on cell pro-
liferation (cells in S-phase) could partly be reversed in 14-
3-3σ knockdown cells. However, complete reversion was
not achieved, most likely be due to the fact that other 5-
Aza-CdR/Pba-induced mechanisms might contribute to
inhibition of melanoma cell proliferation. In line with
these findings, 14-3-3σ stably overexpressing SK-Mel-147
cells (indicated as 14-3-3σ) showed a dramatic reduction
of the fraction of proliferating cells (cells in S-phase). Fig-
ure 4a (lower panel) shows corresponding immunoblots,
indicating that stably shRNAB4 transduced melanoma
Figure 4
14-3-3σ significantly contributes to 5-Aza-CdR/Pba-induced  cell cycle inhibition of melanoma cells Figure 4
14-3-3σ significantly contributes to 5-Aza-CdR/Pba-
induced cell cycle inhibition of melanoma cells. (a) 
Cell cycle analyses were performed for SK-Mel-147 
melanoma cells transduced with empty vector, a functional 
(si14-3-3B4) and non-functional (si14-3-3B7) shRNA, respec-
tively, treated with a combination of 5-Aza-CdR (3 μM) and 
Pba (3 mM) and (upper panel). 14-3-3σ stably ovexpressing 
cells after lentiviral transduction served as positive control. 
Data are given as mean values +/- SD of four independent 
experiments. Asterisks indicate statistical significance of dif-
ferences in the number of cells in S or G2-M between vector 
and si14-3-3σ transduced cells (P < 0.05; Student's t-test). 
Lower panel shows respective immunoblots. (b) Time 
course of cell cycle progression of synchronized SK-Mel-147 
melanoma cells after release of double thymidine block. Data 
are given as mean values +/- SD of four independent experi-
ments. (c) Cell numbers of (b) at different time points after 
release of double thymidine block, together with cell num-
bers from an untreated control culture of SK-Mel-147 
melanoma cells.Molecular Cancer 2009, 8:53 http://www.molecular-cancer.com/content/8/1/53
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cells showed protein expression similar to that of unstim-
ulated melanoma cells, while 14-3-3σ cDNA transduced
cells showed significant upregulation of the 14-3-3σ pro-
tein. Taken together, these findings show that 14-3-3σ
might be an important regulator of melanoma cell growth
via inhibition of cell cycle progression, and loss of its
expression might lead to uncontrolled growth of metas-
tases.
To further substantiate the findings of an inhibitory activ-
ity of 14-3-3σ on cell cycle progression of melanoma cells,
time course experiments were performed. Synchronous
14-3-3σ overexpressing SK-Mel-147 melanoma cells or
control empty vector transduced melanoma cells were
analyzed for cell cycle progression after release of double
thymidine block (Figure 4b and Additional File 2). In
these experiments, the number of cells with 4n DNA con-
tent (diploid cells) was analyzed at indicated time points.
In contrast to empty vector control cells, which normally
progressed through cell cycle, cells stably overexpressing
14-3-3σ showed a stable population of 4n DNA contain-
ing cells for the 24 h period analyzed. Cell numbers were
counted at each time point and synchronization could be
demonstrated for control cells, which doubled 8 h after
release of thymidine block within 4 h. As expected, the
numbers of 14-3-3σ overexpressing, G2-M arrested cells
did not change. Untreated cells showed constant growth
with transition to exponential growth in the late phase of
the 24 h period. In summary, 14-3-3σ significantly
impacts on cell cycle progression in melanoma cells, pre-
dominantly by arresting cells in G2-M phase.
14-3-3σ is involved in cellular senescence of melanoma 
cells
The fact the oncogene-induced senescence is dependent
on intact cell cycle control via tumor suppressor genes
directly interfering with cell cycle such as p16INK,
prompted us to test the possibility that 14-3-3σ might be
involved in melanoma cell senescence. In a first series of
experiments, 14-3-3σ overexpressing and control
melanoma cells were analyzed for senescence-associated
β-galactosidase (SA-β-Gal) activity, a common marker for
cellular senescence [27]. As shown in Figure 5a, 14-3-3σ
overexpressing cells showed a high proportion of senes-
cent cells compared with normal untransduced and
empty vector transduced cells. In order to study the possi-
14-3-3σ induces cellular senescence in melanoma cells Figure 5
14-3-3σ induces cellular senescence in melanoma cells. (a) Expression of senescence marker SA-β-Gal in untransduced, 
vector control or 14-3-3σ cDNA transduced SK-Mel-147 melanoma cells. (b) SK-Mel-19 melanoma cells were exposed to 3.0 
μg/ml adriamycin for indicated time points to induce cellular senescence. Induction of p53, 14-3-3σ and SA-β-Gal was analyzed 
by immunoblotting or immunohistochemistry in untransduced, vector control or 14-3-3σ shRNA (si14-3-3B4) transduced 
cells.Molecular Cancer 2009, 8:53 http://www.molecular-cancer.com/content/8/1/53
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ble contribution of 14-3-3σ to cellular senescence
induced by genotoxic stress, melanoma cells were treated
with chemotherapeutic agent adriamycin. Indeed, adri-
amycin induced p53 and 14-3-3σ in control untransduced
and vector transduced cells which resulted in a significant
number of SA-β-Gal positive cells (Figure 5b). Interest-
ingly, knockdown cells showed a considerably lower
number of senescent cells (Figure 5b). Together, these
findings indicate that 14-3-3σ is an inducer of cellular
senescence of melanoma cells and is involved in the gen-
otoxic stress-induced senescence program of these cells.
Thus, loss of 14-3-3σ and normal senescence program
might contribute to melanoma progression.
Inhibition of 14-3-3σ induces enhanced migration of 
melanoma cells
Finally, we addressed the question whether 14-3-3σ inter-
feres with melanoma cell migration as shown earlier for
colon carcinoma cells [16]. Enhanced migratory capacity
is a particular feature of metastasizing melanoma cells.
For this purpose, a wounding assay was performed. In this
assay cell proliferation was inhibited by addition of mito-
mycin C. As shown in Figure 6, normal control SK-Mel-
147 melanoma cells showed almost complete closure of a
wound in a confluent monolayer after 24 h, whereas 14-
3-3σ overexpression totally inhibited wound closure.
Even after 72 h there was only very limited number of
tumor cells in the wound (data not shown). In contrast,
14-3-3σ knockdown cells showed complete closure of the
wound after 24 h. 14-3-3σ overexpressing cells displayed
a more enlarged and flattened morphology, which had
been described earlier for colon carcinoma cells [15].
Taken together, 14-3-3σ significantly impacts on cellular
migration of melanoma cells. Down-modulation of 14-3-
3σ in melanoma metastases might thereby contribute to
14-3-3σ negatively interferes with melanoma cell migration Figure 6
14-3-3σ negatively interferes with melanoma cell migration. Stably transfected SK-Mel-147 melanoma cells with 
respective empty control vector, 14-3-3σ cDNA and 14-3-3σ shRNA (si14-3-3B4), respectively, were used to test the influ-
ence of 14-3-3σ on melanoma cell migration. A wounding assay was performed and wound closure was analyzed after 24 h. For 
inhibition of cell proliferation 10 μg/ml mitomycin C was added 3 h before wounding of the cell layer.Molecular Cancer 2009, 8:53 http://www.molecular-cancer.com/content/8/1/53
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enhanced migratory capacity of metastatic melanoma
cells.
Discussion
In an earlier large-scale microarray study from our group,
14-3-3σ showed the most significant downregulation in
metastatic melanoma lesions compared with primary
tumors [25]. In the present report, we reconfirmed and
extended these findings in an independent set of speci-
mens, and further addressed the question of the underly-
ing molecular mechanisms and the putative role of 14-3-
3σ in the biology of melanoma metastasis.
Here, we demonstrated that downregulation of 14-3-3σ
expression in metastatic melanoma lesions correlated
with enhanced 14-3-3σ gene methylation. 14-3-3σ gene
methylation indeed appeared to mediate gene silencing
since  in vitro experiments showed that treatment of
melanoma cells with a methylated 14-3-3σ gene with
demethylating agent 5-Aza-CdR (and histone deacetyla-
tion inhibitor Pba) led to dramatic up-regulation of 14-3-
3σ in melanoma cells. In further experiments, 14-3-3σ
overexpressing melanoma cells after 5-Aza-CdR/Pba treat-
ment showed dramatically reduced proliferation rates,
with cells predominantly arrested in G2-M. Furthermore,
14-3-3σ overexpression induced cellular senescence and
was involved in genotoxic stress-induced senescence in
melanoma cells. Moreover, we demonstrated that 14-3-3σ
overexpression significantly reduced migratory capacity of
melanoma cells.
Hypermethylation of the 14-3-3σ gene occurs at a CpG-
rich region (CpG island) within its first exon [21], and
there are series of different malignant tumors with a
hypermethylated 14-3-3σ gene [21-24]. In the study by
Ferguson and co-workers, gene methylation was associ-
ated with reduced 14-3-3σ expression, as 14-3-3σ-nega-
tive breast cancer cell lines were fully methylated at all of
the 27 CpG dinucleotides of this exon [21]. Moreover, in
the mentioned study ten 14-3-3σ-negative primary breast
tumors showed partial or complete methylation of the 27
CpG dinucleotides. Overall, the strong correlation
between methylation status and gene expression suggests
that 14-3-3σ gene expression in primary tumors is signifi-
cantly influenced by epigenetic mechanisms. In a subse-
quent study, Umbricht and co-workers demonstrated that
14-3-3σ is indeed an early event in breast cancer develop-
ment [28]. Authors found hypermethylation of 14-3-3σ in
24 of 25 carcinomas, 15 of 18 ductal carcinomas in situ,
and three of eight of atypical hyperplasias. In contrast,
none of the benign hyperplasias without atypia showed
14-3-3σ hypermethylation. Interestingly, in patients with
preinvasive and invasive breast cancer hypermethylation
extended beyond the margins of the breast cancer tissue
and involved normal breast tissue. The notion of early
silencing of 14-3-3σ during tumor development was sup-
ported by experiments showing that immortalization of
primary epidermal keratinocytes could be achieved only
by 14-3-3σ downmodulation using 14-3-3σ antisense
constructs, without the need of oncogenes or oncoviruses
[29].
Interestingly, none of the currently available studies has
addressed the role of 14-3-3σ in metastatic tumor growth.
Here, we showed that 14-3-3σ was dramatically downreg-
ulated in metastatic lesions from lymph nodes and skin.
Both represent different stages of metastatic spread, i.e.,
loco-regional (lymph node) and distant (skin) metastasis.
In line with the above mentioned findings in primary
tumors, 14-3-3σ downmodulation correlated with levels
of gene methylation. Together, as derived from these find-
ings, 14-3-3σ epigenetic silencing appears to be intensi-
fied as the tumors further progress towards metastasis.
Interestingly, however, levels of gene expression and gene
methylation did not differ between different stages/local-
izations of metastases. It should be mentioned that it is
not conclusive from the present study whether the epige-
netic regulation of 14-3-3σ is directly responsible for the
observed gene silencing effect. Further experimentation is
required to address this issue.
14-3-3 proteins, and in particular 14-3-3σ, play a central
role in cell cycle regulation at different cell cycle check-
points [11,12]. Blocking of 14-3-3σ activity by phospho-
serine peptides containing a conserved 14-3-3 binding
motif led to premature entry into mitosis and so-called
mitotic catastrophe [30]. One of the major mechanisms
by which 14-3-3 proteins exert checkpoint control is by
sequestration of 14-3-3-interacting cell cycle molecules
from the nucleus into cytoplasm. 14-3-3 interacting pro-
teins are for example CDC25C and CDC25B, dual-specif-
icity phosphatases and activators of cyclin-dependent
kinase CDC2, the central kinase for driving cells through
mitosis. During interphase, premature activation of CDC2
is prevented by inactivation of both CDC25 proteins by
14-3-3-mediated cytoplasmic sequestration. 14-3-3σ,
however, does not directly interact with CDC25C, but
appears to negatively regulate mitosis by sequestration of
CDC2-cyclin B complexes [31]. The exact functional role
of 14-3-3σ binding to CDC25B remains to be determined.
14-3-3σ also binds to cyclin dependent kinases CDK2 and
CDK4, both of which are active during G1, and might
thereby contribute to G1 arrest [32]. Moreover, 14-3-3
proteins bind to and inactivate CDC25A by cytoplasmic
sequestration. CDC25A dephosphorylates CDK2 on its
inhibitory phosphates and thereby promotes S-phase
entry. Binding to CDC25A has, however, not yet been
shown for 14-3-3σ. Together, the major effects of 14-3-σ
appear to be in G2-M, but entry into cell cycle (G0-G1)
might also be affected [12,15].Molecular Cancer 2009, 8:53 http://www.molecular-cancer.com/content/8/1/53
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By use of 5-Aza-CdR alone or in a combination with Pba,
we induced high levels of 14-3-3σ in melanoma cells in
vitro. Parallel cell cycle analyses by flow cytometry showed
that the number of cells in S-phase was dramatically
reduced, with a shift of cells to G2-M and to a lesser extend
to G0-G1. Similar results were obtained in 14-3-3σ stably
overexpressing cells. Together, these findings indicated
that 14-3-3σ leads to cell cycle arrest of melanoma cells
mainly in G2-M. In line with this, synchronized 14-3-3σ
overexpressing cells showed a invariable number of 4n
DNA containing cells in time course experiments, while
control cells normally progressed through cell cycle. Sim-
ilar findings have been reported earlier in colon carci-
noma cells [15].
Interestingly, recently published data indicated that 14-3-
3σ also plays role in mitotic exit [33]. Authors demon-
strated a previously unknown function for 14-3-3σ as a
regulator of mitotic translation through its direct mitosis-
specific binding to a variety of translation/initiation fac-
tors. Cells lacking 14-3-3σ could not suppress cap-
dependent translation and did not stimulate cap-inde-
pendent translation during and immediately after mitosis.
This defective switch in the mechanism of translation
resulted in impaired cytokinesis and the accumulation of
binucleate cells. This was regarded as a potential explana-
tion of how 14-3-3σ-deficient cells progress on their way
to aneuploidy, a characteristic feature of malignant trans-
formation. The fact that 14-3-3σ is further downregulated
in metastatic tumor cells, as exemplified by our study,
might explain high levels of aneuploidy in metastatic
tumor cells [34,35].
In a further series of experiments, we addressed the ques-
tion, whether 14-3-3σ might be involved in regulation of
cellular senescence of melanoma cells, as cellular senes-
cence is tightly linked to cell cycle control and activation
of tumor suppressor p53 in many cell types [36]. SA-β-Gal
activity is strongly expressed in benign melanocytic nevi,
the common precursors of malignant melanoma [37].
However, it remains to be determined whether the normal
cellular senescence program might be compromised in
primary or metastatic melanoma lesions. The p19ARF/p53-
and Rb/p16INK4a-dependent pathways mediate cellular
senescence after oncogene stimulation in a variety of pre-
malignant and malignant tumors including malignant
melanoma [36,38]. However, evidence has been provided
that an Rb/p16 independent mechanism via inactivation
of T-box transcription factor Tbx2, which is overexpressed
in melanomas, can also lead to melanoma cell senescence
[39]. This mechanism appears may involve p53 and
p21Cip1, as Tbx2 and Tbx3 are potent repressors of p21Cip1.
Since p53 is upregulated in a positive feedback loop via
14-3-3σmediated inhibition of p53 ubiquitinating
HDM2 [17,18], overexpression of 14-3-3σ might over-
come this senescence block in melanoma cells, or down-
regulation of 14-3-3σ might be supportive for defective
senescence program. Indeed, we demonstrated that 14-3-
3σ overexpression induced cellular senescence in vitro.
Moreover, stress-induced senescence by chemotherapeu-
tic agent adriamycin was at least in part dependent on 14-
3-3σ expression, as 14-3-3σ knockdown cells showed sig-
nificantly less senescent cells. Thus, 14-3-3σ may over-
come defective senescence programs in melanoma cells.
In line with recent reports showing that cellular senes-
cence of human melanocytes involved histone deacetylase
1 (HDAC1) [40,41], which deacetylates histone lysine res-
idues as a major prerequisite for histone H3K9 methyla-
tion, we found significant H3K9 methylation in
adriamycin-induced 14-3-3σ mediated senescence (data
not shown).
A more direct role of 14-3-3σ in cellular senescence was
shown earlier [29]. Authors showed that 14-3-3σ is abun-
dantly expressed in the suprabasal differentiated layers of
human epidermis. Moreover, its downregulation allows
keratinocytes to escape replicative senescence by impair-
ing clonal evolution. Downregulation of 14-3-3σ was
accompanied by the maintenance of telomerase activity
and by a strong downregulation of the p16INK4a tumor
suppressor gene. Together, based on our findings and the
mentioned data from other groups, loss of a functional
senescence pathway via 14-3-3σ downmodulation might
be a further mechanism for melanoma metastasis in vivo.
Finally, we tested the capacity of 14-3-3σ to interfere with
cellular migration of melanoma cells. It is well under-
stood that enhanced migratory capacity is a characteristic
of metastatic tumor cells [35,42]. In a recent study using
tandem affinity purification and the multidimensional
protein identification technology 117 proteins were iden-
tified as interaction partners for 14-3-3σ in human cells
[16]. Many of these were involved in mitogenic signalling
and cell cycle. However, the largest functional class was
represented by 36 proteins involved in cellular migration,
including RhoE, RhoGEF16 and RhoGEF17, Rac GTPase-
activating protein 1, C-terminal tensin-like and ladinin. In
line with this, we observed strong migratory inhibitory
effects on melanoma cells in a wounding assay. Thus,
downregulated 14-3-3σ in melanoma cells might lead to
increased motility and further support tumor metastasis.
Similar results were reported for the 14-3-3σ overexpress-
ing DLD1 colon cancer cell line [16].
Conclusion
In summary, epigenetic silencing of 14-3-3σ in melanoma
metastases might contribute to tumor progression via loss
of cell cycle control and control of cellular senescence pro-
grams as well as by support of melanoma cell migratory
capacity.Molecular Cancer 2009, 8:53 http://www.molecular-cancer.com/content/8/1/53
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Methods
Melanoma tissues and cell lines
For quantitative real-time PCR (qPCR) and methylation-
specific PCR (MSP) two independent sets of melanoma
specimens were used. The first set (qPCR) consisted of 11
primary melanomas, 10 lymph node metastases and 12
cutaneous metastases, respectively. The second set (MSP)
consisted of 15 primary melanomas, 20 lymph node
metastases and 19 cutaneous metastases. More detailed
information about primary melanomas including tumor
subtype, tumor thickness and clinical stage is given in
Additional Files 3 and 4. These studies were performed
according to the Principles of the Declaration of Helsinki
and were approved by the local Ethics Committee at the
University of Rostock. Biopsies were obtained from
patients after informed consent. The human melanoma
cell lines SK-Mel-19, SK-Mel-29, and SK-Mel-147 were
kindly provided by M. Soengas, Department of Dermatol-
ogy, University of Michigan, Ann Arbor, MI, U.S.A. [38].
Cell cultures were maintained in DMEM medium supple-
mented with 10% fetal calf serum and 100 μg penicillin-
streptomycin ml-1.
RNA purification and real-time RT-PCR
For 14-3-3σ mRNA expression analysis in primary
melanomas and metastases laser-capture microdissection
of tissues was performed as described earlier [25]. Total
RNA was extracted from laser-microdissected melanoma
cells, using a commercially available RNA extraction Kit
(RNeasy®, Qiagen, Hilden, Germany). RNA concentra-
tions were determined with a NanoDrop® ND-1000 spec-
trophotometer (NanoDrop Technologies, Wilmington,
DE, USA), and RNA quality was tested with an Agilent
2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA,
USA). A commercially available TaqMan® real-time PCR
assay was performed (Assays-on-Demand®, Applied Bio-
systems, Darmstadt, Germany). Ten ng of total RNA were
used in each reaction and reverse transcription of RNA
templates and PCR amplification were carried out with
the TaqMan EZ RT-PCR® Kit using an ABI PRISM® 7700
system (Applied Biosystems). Data were normalized to
GAPDH expression.
Methylation-specific PCR (MSP)
Genomic DNA was extracted from laser-microdissected
tissues from primary melanomas and melanoma metas-
tases using DNeasy™ Tissue Kit (Qiagen). One μg of DNA
was treated with sodium bisulfite using CpGenome™ Fast
DNA Modification Kit (Chemicon, Hofheim, Germany).
Subsequently, methylation-specific PCR (MSP) was per-
formed with a primer set that covered CpG dinucleotide
numbers 3, 4, 8 and 9 [21]. Primers specific for methyl-
ated DNA had the sequence: 5'-TGGTAGTTTTTAT-
GAAAGGCGTC-3' (sense) and 5'-
CCTCTAACCGCCCACCACG-3' (antisense), primers spe-
cific for unmethylated DNA had the sequence: 5'-ATGG-
TAGTTTTTATGAAAGGTGTT-3' (sense) and 5'-
CCCTCTAACCACCCACCACA-3' (antisense). Sizes of
amplification products were 105 bp and 107 bp, respec-
tively. The PCR conditions were as follows: 1 cycle of
95°C for 5 min; 30 cycles of 95°C for 45 s, 56°C for 30 s
and 72°C for 30 s; and 1 final cycle of 72°C for 10 min.
PCR products were separated on 1% agarose gels and
stained with ethidium bromide. For quantification of PCR
products the volumes of the different bands of the gel
were analyzed using Progenesis PG200 software (Nonlin-
ear Dynamics, Newcastle, UK). Experimental results were
expressed as per cent methylated band signal.
5-Aza-CdR and Pba treatment of cell lines
SK-Mel-19, SK-Mel-29 and SK-Mel-147 melanoma cells
(1.5 × 106) were treated with 5-Aza-CdR (3 μM; Sigma-
Aldrich, Munich, Germany), Pba (3 mM; Sigma Aldrich),
or a combination of both for 72 h or left untreated. 5-Aza-
CdR was removed after 24 h, while Pba was administered
continuously during the 72 h period by replacement of
medium.
Antibodies and immunoblotting
Melanoma cell lines were lysed on ice for 30 min using
radioimmunoprecipitation (RIPA) buffer. Forty μg of
total protein were denatured in electrophoresis sample
buffer for 5 min at 95°C and subjected to SDS-polyacryla-
mide gel electrophoresis (PAGE). Gels were electroblotted
onto nitrocellulose membranes (Highbond ECL®, Amer-
sham, Braunschweig, Germany) and subjected to immun-
odetection. The following primary antibodies were used:
anti-14-3-3σ mouse monoclonal antibody (ab14123,
abcam/BIOZOL, Eching, Germany), anti-p53 mouse
monoclonal antibody (cat. no. 554293, BD Biosciences;
Heidelberg, Germany), anti-β-tubulin rabbit polyclonal
antibody (sc-9104, Santa Cruz Biotechnology, Heidel-
berg, Germany). Signal detection was performed by
appropriate secondary anti-mouse or anti-rabbit antibod-
ies, coupled with horseradish peroxidase (Santa Cruz Bio-
technology). A standard ECL (enhanced
chemoluminescence) reaction (Amersham) was per-
formed for signal visualization. Relative expression levels
of 14-3-3σ and p53 in immunoblots were analyzed by
ImageJ software and normalized to tubulin expression
http://rsbweb.nih.gov/ij/.
Lentiviral 14-3-3σ shRNA or cDNA transduction
To establish SK-Mel-147 and SK-Mel-19 14-3-3σ knock-
down cells, a vector-based shRNA technique was used. A
set of seven different shRNAs cloned into pLKO.1 vector
(RHS4533, Human pLKO.1 lentiviral shRNA target gene
set; Open Biosystems, Huntsville, AL, U.S.A.) was used.
Recombinant lentiviruses were produced by co-transfect-
ing human embryonic kidney (HEK) 293 T cells with eachMolecular Cancer 2009, 8:53 http://www.molecular-cancer.com/content/8/1/53
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14-3-3σ shRNA lentiviral expression plasmid together
with packaging plasmids pTLA1-Pak, pTLA1-Enz, pTLA1-
Env, pTLA1-Rev and pTLA1-TOFF (Translentiviral shRNA
Packaging System; Open Biosystems) using Effectene™
(Qiagen) as a transfection reagent. HEK 293 T cells were
cultured in DMEM supplemented with 10% FCS, 100 μg
penicillin-streptomycin ml-1, in a 37°C incubator with
5% CO2. Infectious lentiviruses were collected 48 h after
transfection. The supernatant was centrifuged, filtered
through 0.45 μm filters (Millipore, Carrigtwohill, Ireland)
and concentrated by centrifugation with 50 000 g at 4°C
for 90 min. After transduction melanoma cells were put in
selection medium containing 1% puromycin. This
medium was replaced by normal culture medium 24 h
before start of experiments. 14-3-3σ gene knockdown was
tested by quantitative PCR. The shRNA with the most sig-
nificant (80%) knockdown, called si14-3-3-B4
(TRC0000040128; Open Biosystems), and one non-func-
tional shRNA, called si14-3-3-B7 (TRC0000040131;
Open Biosystems) were used in further functional experi-
ments.
For stable transduction of SK-Mel-147 melanoma cells
with 14-3-3σ cDNA, 14-3-3σ cDNA was cut out of a com-
mercially available cDNA expression plasmid
(pcDNA3.1/hisC14-3-3sigma; addgene, Germany) by
restriction enzyme digest, using BamHI and EcoRI restric-
tion enzymes. The resulting fragment was cloned into the
lentiviral expression vector pCDF1-MCS1-EF1-Puro (Sys-
tem Biosciences, Moutain View, CA, U.S.A.), which was
used for stable transduction of melanoma cells. Infectious
lentiviruses were produced using the pPACKF packaging
system (System Biosciences). Again, after transduction
melanoma cells were put in selection medium containing
1% puromycin. This medium was replaced by normal cul-
ture medium 24 h before start of experiments.
Cell cycle analysis
For cell cycle analysis, SK-Mel-147 melanoma cells were
stained using an FITC BrdU Flow Kit (BD Biosciences).
Populations in G0-G1, S and G2-M phase were measured
by flow cytometry with a FACSCalibur (BD Biosciences).
Data were processed and analyzed by CellQuest™ Soft-
ware (BD Biosciences). For time course experiments of cell
cycle, SK-Mel-147 melanoma cells were subjected to dou-
ble thymidine block (early S-phase block) for synchroni-
zation. For this purpose, cells were grown at 2530%
confluency, washed twice with 1 × PBS and subsequently
grown in DMEM medium supplemented with 10% fetal
calf serum and 100 μg penicillin-streptomycin ml-1and 2
mM thymidine (Sigma-Aldrich) for 18 h (first block).
After that first block thymidine was removed by washing
with 1 × PBS, fresh medium was added for 9 h to release
cells. After releasing again medium with 2 mM thymidine
was added for 17 h (second block). After the second block
thymidine was removed by washing with 1 × PBS and cells
were released by adding fresh DMEM medium. Cells then
progress synchronously through G2 and mitotic phase.
For measurement of 4n  DNA containing cells by flow
cytometry, cells were stained with propidium iodide
(Sigma-Aldrich). To confirm synchronization of
melanoma cells, cell numbers were counted at each time
point and compared with cell numbers of untreated cells
from a parallel culture.
Detection of cellular senescence
A commercially available system was used for detection of
SA-β-Gal expression (Senescence Cell Histochemical
Staining Kit, Sigma-Aldrich) and the staining of cells was
performed as recommended by the manufacturer. SK-
Mel-147 melanoma cells were stained with an X-gal con-
taining staining mixture for 4 h at 37°C and blue-stained
cells and total number of cells was counted by micro-
scopic inspection.
Wounding Assay
SK-Mel-147 melanoma cells were seeded into 6-well
plates at 7080% confluency. To prevent proliferation dur-
ing wounding assay, cells were treated with 10 μg/ml
mitomycin C (Sigma-Aldrich) for 3 h. The cell monolayer
was then scratched in the middle with a plastic tip. Cell
migration was monitored by optical inspection for 24 h
using an Olympus microscope (Olympus, Hamburg, Ger-
many) and pictures were taken at 0 and 24 h.
Statistical analysis
Copy numbers of 14-3-3σ mRNA analyzed by quantita-
tive real-time RT-PCR, the percentage of methylated 14-3-
3σ alleles and percentage of senescent cells are given as
mean +/- SD or +/- S.E.M, as indicated. For analysis of sta-
tistical significance after testing of normal distribution of
values a Student's t-test was performed. Data with P ≤ 0.05
were regarded as statistically significant.
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